Change of Nerve Conduction Properties in IVIg Dependent Neuropathies

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01655394

Enrollment

Registered

2012-08-01

Start date

2012-10-31

Completion date

2016-06-30

Last updated

2014-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CIDP, Guillain-Barre Syndrome, Multifocal Motor Neuropathy

Brief summary

IVIg exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction in patients with immune-mediated neuropathies will be explored.

Detailed description

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* immune neuropathy * age above 18 y * IVIg treatment exclusion: * no IVIg treatment

Design outcomes

Primary

Measure	Time frame
Clinical Improvement	6 Months

Countries

Germany

Outcome results